KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to -$7.2 billion.

  • Alnylam Pharmaceuticals' Retained Earnings rose 60.47% to -$7.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 billion, marking a year-over-year increase of 60.47%. This contributed to the annual value of -$7.3 billion for FY2024, which is 396.82% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Retained Earnings of -$7.2 billion as of Q3 2025, which was up 60.47% from -$7.4 billion recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Retained Earnings peaked at -$4.8 billion during Q1 2021, and registered a low of -$7.4 billion during Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Retained Earnings value was -$6.9 billion (recorded in 2023), while the average stood at -$6.5 billion.
  • In the last 5 years, Alnylam Pharmaceuticals' Retained Earnings tumbled by 2282.21% in 2022 and then soared by 60.47% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Retained Earnings (Quarter) stood at -$5.4 billion in 2021, then fell by 20.8% to -$6.6 billion in 2022, then dropped by 6.7% to -$7.0 billion in 2023, then fell by 3.97% to -$7.3 billion in 2024, then rose by 1.75% to -$7.2 billion in 2025.
  • Its Retained Earnings was -$7.2 billion in Q3 2025, compared to -$7.4 billion in Q2 2025 and -$7.3 billion in Q1 2025.